NASDAQ: SGMO
Sangamo Therapeutics is a genomic medicine company focused on developing treatments for serious neurological diseases with unmet medical needs. The company leverages zinc finger protein technology to create epigenetic regulators and uses a proprietary capsid discovery platform (STAC-BBB) for central nervous system delivery via adeno-associated virus (AAV) vectors. Its most advanced wholly owned program is isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease currently undergoing a rolling BLA submission to the FDA under an Accelerated Approval pathway. The neurology pipeline includes ST-503 for chronic neuropathic pain due to small fiber neuropathy (Phase 1/2) and ST-506 for prion disease (preclinical). Sangamo also generates revenue through collaboration and licensing agreements with partners including Pfizer, Sigma-Aldrich, and Miltenyi Biotec. The company trades on the OTCQB Venture Market under the ticker SGMO and is actively seeking a commercialization partner for its Fabry disease program as well as additional funding to sustain operations. Updated
Tuesday's top analyst upgrades and downgrades included American Tower, Best Buy, Dominion Energy, Intuit, NetEase, Shell, Southwest Airlines, State Street and Union Pacific.
Monday's additional top analyst upgrades and downgrades included BioMarin Pharmaceutical, Micron Technology, Quanta Services, Sangamo Therapeutics, Silvergate Capital, T. Rowe Price and Zendesk.
Tuesday's top analyst upgrades and downgrades included Ambarella, Annaly Capital Management, Cinedigm, Fortinet, Kinder Morgan, 3M, Nikola, Nvidia, Tesla, Uber Technologies and YETI.
Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many cases it is far cheaper to just partner up with these smaller…
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg and PG&E.
The top analyst upgrades, downgrades and initiations seen on Friday included ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks Solutions, TripAdvisor, YRC Worldwide and Yelp.
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should…
While some of the price targets discussed here call for a stock to double, or even to rise exponentially, it is important to understand that there is a much larger risk when…
Jefferies has picked out a few companies in the biotech industry that stand to win big over the coming year.
Sangamo Therapeutics is a genomic medicine company focused on developing treatments for serious neurological diseases with unmet medical needs.
